Inlay

"Thus, PD-1 signaling is not simply a brake. It also preserves stemness...therapies such as interleukin-7 that restore or stabilize these renewable compartments may extend the long-term benefit of checkpoint inhibition." 🧪🩺

The clinical benefits of checkpoint inhibitors in the treatment of cancer often wane. A preclinical study points to a potential strategy for a more durable effect.